“We have now found that CBD appears to buffer the user against some of the acute effects of THC on the brain,” said the study’s lead author, Dr Matt Wall. Hemp-derived CBD products (with less than 0.3 percent THC) are legal on the federal level, but are still illegal under some state laws. Marijuana-derived CBD products are illegal on the federal level, but are legal under some state laws.
While there isn’t evidence at curing these diseases with CBD oil, there may be evidence showing how it slows these conditions. An antioxidant is a substance that inhibits oxidation, a chemical reaction that produces free radicals. These free radicals can damage cells and eventually lead to certain diseases and illnesses. By working as an antioxidant, CBD may slow the progression of damaging cells related to neurodegenerative diseases.
In human AD patients, cellular studies of senile plaques have shown expression of cannabinoid receptors CB1 and CB2, together with markers of microglial activation. Control CB1-positive neurons, however, are in greater numbers compared to AD areas of microglial activation. AD brains also have markedly decreased G-protein receptor coupling and CB1 receptor protein expression. Activated microglia cluster at senile plaques is generally believed to cbc oil be responsible for the ongoing inflammatory process in the disease.
I really, truly hope the best for everyone on this site, because I understand you. Again I have health anxiety issues that I have largely overcome or learned to live with. I am only immortal for a limited time and I accept that most of the time. I was watching a YouTube video that mentioned health anxiety and people using an illegal drug in small doses to combat it. I wondered if there was any scientific evidence for the comments and ended up reading the above which was very informative.
CBD’s action with the CB2 receptor is just one of several pathways by which CBD can affect neuroinflammation [Table 2]. Anecdotally, this effect is noted by many cannabis users who co-ingest CBD. Cannabinoid receptor pharmacology began in the late 1960s when Δ9-THC was isolated and synthesized and found to be the primary psychoactive constituent of marijuana. The discovery in the early 1990s of specific membrane receptors for Δ9-THC led to the identification of endogenous signaling system, now known as the endocannabinoid system (ECS).